Amundi Sells 698,283 Shares of QIAGEN N.V. $QGEN

Key Points

• Amundi reduced its holdings in Qiagen N.V. by 13.8% during the first quarter, selling 698,283 shares and owning approximately 1.96% of the company at a value of $175.76 million.
• Equities analysts have diverse opinions on Qiagen, with three analysts rating it as a Buy and eight giving it a Hold rating; the current consensus price target is $49.69.
• Qiagen reported earnings of $0.60 EPS for the quarter, matching expectations, with revenues of $533.54 million, reflecting a 7.7% increase year over year.

Amundi cut its holdings in QIAGEN N.V. (NYSE:QGEN - Free Report) by 13.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,353,734 shares of the company's stock after selling 698,283 shares during the period. Amundi owned 1.96% of QIAGEN worth $175,760,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in QGEN. SVB Wealth LLC purchased a new position in QIAGEN during the 1st quarter valued at about $31,000. ANTIPODES PARTNERS Ltd purchased a new position in QIAGEN during the first quarter valued at approximately $94,000. Tower Research Capital LLC TRC increased its holdings in QIAGEN by 770.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock worth $111,000 after acquiring an additional 2,204 shares during the period. GAMMA Investing LLC raised its position in shares of QIAGEN by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after buying an additional 1,425 shares in the last quarter. Finally, Federated Hermes Inc. bought a new stake in QIAGEN during the first quarter valued at $150,000. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

QIAGEN Trading Down 1.1%

QIAGEN stock traded down $0.50 during trading hours on Tuesday, reaching $47.08. The stock had a trading volume of 903,831 shares, compared to its average volume of 1,385,979. The company has a fifty day simple moving average of $48.65 and a 200-day simple moving average of $44.48. QIAGEN N.V. has a 52 week low of $37.63 and a 52 week high of $51.88. The stock has a market cap of $10.47 billion, a PE ratio of 27.82, a PEG ratio of 2.51 and a beta of 0.64. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35.

QIAGEN (NYSE:QGEN - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting analysts' consensus estimates of $0.60. The company had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. QIAGEN's revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.55 earnings per share. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Analysts forecast that QIAGEN N.V. will post 2.26 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on QGEN shares. Cowen reissued a "hold" rating on shares of QIAGEN in a report on Thursday, August 7th. Bank of America lifted their price target on QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. Barclays began coverage on QIAGEN in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price objective on the stock. UBS Group boosted their target price on QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Finally, Wall Street Zen cut shares of QIAGEN from a "strong-buy" rating to a "buy" rating in a research report on Monday, August 11th. Three analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, QIAGEN presently has a consensus rating of "Hold" and an average price target of $49.69.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.